Akero Therapeutics Inc (AKRO) |
|
34.61 0.15 (0.44%)
|
08-13 16:00 |
|
Open: |
34.04 |
Pre. Close: |
34.46 |
|
High:
|
35.19 |
Low:
|
33.94 |
|
Volume:
|
246,839 |
Market Cap:
|
1,201M |
|
|
|
|
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
35.24 - 35.438 |
35.438 - 35.618 |
|
Low:
|
33.423 - 33.679 |
33.679 - 33.914 |
|
Close:
|
34.237 - 34.61 |
34.61 - 34.952 |
|
Technical analysis |
as of: 2020-08-13 4:31:25 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 43.23  One year: 46.49 |
| Support: |
Support1: 32.50 Support2: 27.04 |
| Resistance: |
Resistance1: 37.01 Resistance2: 39.80 |
| Pivot: |
35.73 |
| Moving Average: |
MA(5): 34.87 MA(20): 36.02
MA(100): 26.67  MA(250): 23.72 |
| MACD: |
MACD(12,26): 0.57 Signal(9): 1.12 |
| Stochastic oscillator: |
%K(14,3): 23.62 %D(3): 21.74 |
| RSI: |
RSI(14): 49.52 |
| 52-week: |
High: 41.16 Low: 10.78 Change(%): 31.4 |
| Average Vol(K): |
3-Month: 37593 10-Days: 22214 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.AKRO has closed above bottom band by 17.9%. Bollinger Bands are 51.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to AKRO's normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 13 Aug 2020
H.C. Wainwright Stick to Their Buy Rating for Akero Therapeutics Inc - Investing.com
Wed, 12 Aug 2020
Akero Therapeutics Reports Second Quarter 2020 Financial Results - PRNewswire
Mon, 10 Aug 2020
may delivered a positive earnings surprise Akero Therapeutics (NASDAQ:AKRO) - Stock Market Daily
Thu, 30 Jul 2020
How Much Of Akero Therapeutics, Inc. (NASDAQ:AKRO) Do Institutions Own? - Simply Wall St
Wed, 22 Jul 2020
Akero Therapeutics Inc. (AKRO): Choosing The Technical Investor Route - The Comet Reports
Tue, 21 Jul 2020
Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics' NASH Therapeutic Candidate - PRNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NasdaqGS |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
35 |
| Shares Float (M) |
14 |
|
% Held by Insiders
|
9.51 |
|
% Held by Institutions
|
84.23 |
|
Shares Short (K)
|
1,120 |
|
Shares Short P. Month (K)
|
569 |
Stock Financials |
|
EPS
|
-2.270 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
4.130 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-33.0 |
|
Return on Equity (ttm)
|
-53.5 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-42 |
|
Levered Free Cash Flow (M)
|
-24 |
Stock Valuations |
|
PE Ratio
|
-15.25 |
|
PEG Ratio
|
|
|
Price to Book value
|
8.38 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-28.94 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
